Bosentan

Routes
Oral (PO)
Half-Life (t½)
PO: 5h
Formula
C27H29N5O6S
Molecular Weight
551.62 g/mol
PubChem CID
104865
Aliases
Tracleer

Pharmacological Mechanism

Dual endothelin-A + B receptor antagonist — blocks vasoconstrictive + proliferative effects of endothelin-1 on pulmonary vasculature. Approved for pulmonary arterial hypertension. Hepatotoxicity (REMS program) + teratogenicity. Strong CYP3A4 inducer.

Half-Life & Elimination Curve (PO: 5h)

100%50%25%12.5%0%0h0×t½5h1×t½10h2×t½15h3×t½20h4×t½25h5×t½0×t½ (0h): 100% remaining (~2.28 mg/L)1×t½ (5h): 50% remaining (~1.14 mg/L)2×t½ (10h): 25% remaining (~0.571 mg/L)3×t½ (15h): 12.5% remaining (~0.285 mg/L)4×t½ (20h): 6.3% remaining (~0.143 mg/L)5×t½ (25h): 3.1% remaining (~71.4 µg/L)
Plasma (PO)t½ Decay (5h)Effect Site (ke0)
  • 0×t½0h100% (2.28 mg/L)
  • 1×t½5h50% (1.14 mg/L)
  • 2×t½10h25% (0.571 mg/L)
  • 3×t½15h12.5% (0.285 mg/L)
  • 4×t½20h6.3% (0.143 mg/L)
  • 5×t½25h3.1% (71.4 µg/L)
Elimination t½5h (PO)
Rate Constant (ke)0.139 h⁻¹
Time to Peak (Tmax)3.02h
Est. Peak (Cmax)2.28 mg/L
Clearance (CL)2.5 L/h
97% Washout (5×t½)25h

Dosing Guidelines

Pharmacokinetic Parameters

Receptor Binding & Occupancy

Pathways It Modulates

Target Organ Systems

Interactions

Chemical Structure & Identifiers

References